异种移植市场－全球产业规模、份额、趋势、机会及预测（依动物类型、异种产品、器官、最终用户、地区及竞争格局划分，2021-2031年）

全球异种移植市场预计将经历强劲成长，预计从 2025 年的 157.3 亿美元成长到 2031 年的 265.4 亿美元，复合年增长率为 9.11%。

这个领域涉及将源自非人类动物的活细胞、组织或器官移植、植入或输注到人类受体。推动该市场发展的关键因素是器官移植需求旺盛而人类捐赠者器官短缺之间的巨大缺口，以及基因工程技术的进步如何缓解免疫不相容问题。根据器官捐赠与移植联盟的数据，2024年全球仅进行了172,397例固态器官移植手术，凸显了器官严重短缺的现状，也因此亟需这些替代治疗方案。

阻碍市场扩张的一大障碍是人畜共通传染病的风险，即感染疾病感染疾病动物通用传播给人类患者。这项安全隐患要求严格的筛检程序和监管，可能会延缓异种移植产品的核准流程和商业化进程。因此，儘管这项技术有潜力满足对器官的迫切需求，但要成功推向市场，仍需进行广泛的安全检验以防止跨物种传播，这是该行业必须克服的关键挑战。

市场驱动因素

全球持续存在的人类器官短缺是异种移植领域发展的主要驱动力。这是由于可用器官数量与等待移植的患者人数之间的差距日益扩大所致。可用的人类器官短缺迫切需要研究非人类替代器官，以防止等待移植的患者死亡。例如，美国卫生资源和服务管理局 (HRSA) 在 2024 年 3 月报告称，仅在美国国家器官移植等待名单上就有超过 10.3 万人。这一巨大的缺口凸显了开发可扩展解决方案（例如异种移植）的迫切需求，以帮助那些在无法及时找到匹配的人类捐赠者的情况下，患有终末期器官衰竭的患者。

此外，基因编辑和基因工程技术的进步正在加速市场成长，因为它们克服了以往阻碍成功的免疫学障碍。例如，CRISPR-Cas9技术使科学家能够修改猪的基因组，去除导致超急性排斥反应的抗原，并插入人类基因以提高相容性。一个典型的例子是，2024年3月在麻省总医院进行的全球首例基因编辑猪肾移植手术，手术涉及69处基因组编辑。这些方法的商业性可行性也得到了大量资金的支持，例如eGenesis在2024年获得的1.91亿美元D轮资金筹措，用于推进其异种移植产品线进入临床试验阶段。

市场挑战

通用感染疾病，特别是动物供体向人类受体传播病原体的风险，构成了阻碍全球异种移植市场成长的主要障碍。这项安全问题促使监管机构强制要求实施严格的预防措施，例如建立生物安全养殖设施，并对猪内源性逆转录病毒等病原体进行彻底筛检。这些严格的要求显着增加了研发的复杂性和成本，延长了临床试验週期，并延缓了异种移植产品从试验阶段转化为商业性化治疗方法的影响。

此外，由于无法快速检验安全标准，阻碍了企业扩张以满足器官移植的巨大且迫切的需求，导致很大一部分潜在市场尚未开发。这套颈部阻碍了能够弥合供需缺口的技术的广泛应用。正如美国器官共享联合网络（UNOS）在2024年指出的那样，美国有超过10万人处于器官移植等待名单上，但仅进行了48149例移植手术。这种差距凸显了巨大的市场机会仍未得到充分利用，这主要是由于通用感染疾病安全方面的挑战尚未解决，以及监管机构因此而采取的谨慎态度。

市场趋势

该领域的一个关键转折点是从临床前研究和零星的仿单标示外用药案例过渡到结构化的、经监管机构核准的「首次人体临床试验」。这一转变标誌着该行业在收集生技药品核准申请所需的标准化安全性和有效性数据方面取得了进展，从而建立了一条清晰的商业性核准路径，并证明了基因编辑器官生产的可扩展性。例如，联合治疗公司（United Therapeutics）于2025年2月宣布，其临床实验申请（IND）已获得美国食品药物管理局（FDA）的核准，可以招募其UKidney异种移植临床试验的首批六名患者。

同时，肾臟异种移植的商业性化已成为一项重要的策略重点，各公司纷纷将目光投向肾臟病领域。这是因为与心臟或肝臟手术相比，透析作为一种替代疗法，可以降低移植失败导致的近期死亡风险。儘管透析起到了一定的安全保障作用，但其限制也进一步凸显了此适应症的紧迫性。 2025年9月，在EGEN-2784获得IND核准后，eGenesis公司报告称，透析患者的五年死亡率超过50%。这项数据凸显了市场对一种可行的异种移植替代方案的迫切需求，该方案能够弥补现有肾臟替代疗法的不足。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球异种移植市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依动物种类（猪、兔子、狒狒等）
  • 异种移植产品（器官、组织、细胞）
  • 依器官分类（肾臟、肝臟、心臟、角膜等）
  • 按最终使用者（移植中心、医院等）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章 北美异种移植市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲异种移植市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区异种移植市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲异种移植市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲异种移植市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球异种移植市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• United Therapeutics Corporation
• eGenesis, Inc.
• Novartis AG
• Astellas Pharma, Inc.
• F. Hoffmann-La Roche Ltd.
• Preservation Solutions, Inc.
• OrganOX Limited
• TransMedic, Pte. Ltd.
• Pfizer, Inc.
• Makana Therapeutics

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Xenotransplantation Market is projected to experience robust growth, expanding from a valuation of USD 15.73 Billion in 2025 to USD 26.54 Billion by 2031 at a compound annual growth rate of 9.11%. This sector encompasses the transplantation, implantation, or infusion of live cells, tissues, or organs derived from nonhuman animal sources into human recipients. The market is primarily driven by the critical gap between the high demand for organ replacements and the scarce supply of human donors, alongside breakthroughs in genetic engineering that mitigate immune incompatibility. Data from the Organ Donation and Transplantation Alliance in 2024 indicated that only 172,397 solid organ transplants were conducted globally, underscoring the severe shortage that necessitates these alternative therapeutic solutions.

One significant obstacle potentially hindering market expansion is the risk of zoonosis, which entails the transmission of infectious diseases from animal hosts to human patients. This safety concern mandates rigorous screening protocols and strict regulatory oversight, which can delay the approval processes and commercial availability of xenotransplantation products. Consequently, while the technology promises to address the urgent need for organs, the requirement for extensive safety validation to prevent cross-species infection remains a critical challenge that the industry must navigate to ensure successful market adoption.

Market Driver

The persistent global shortage of human donor organs acts as the primary catalyst for the xenotransplantation sector, fueled by the widening disparity between available organs and the growing number of patients on waiting lists. This unavailability of viable human organs necessitates urgent research into nonhuman alternatives to prevent mortality among patients waiting for transplants; for instance, the Health Resources and Services Administration reported in March 2024 that over 103,000 individuals were on the U.S. national transplant waiting list alone. This substantial gap highlights the critical need for scalable solutions like xenotransplantation to support patients suffering from end-stage organ failure who are unable to secure human donor matches in a timely manner.

Additionally, advancements in gene editing and genetic engineering technologies are accelerating market growth by overcoming the immunological barriers that have historically prevented successful cross-species transplantation. Technologies such as CRISPR-Cas9 enable scientists to modify porcine genomes by removing antigens that trigger hyperacute rejection and inserting human genes to enhance compatibility, as demonstrated by Massachusetts General Hospital's March 2024 report on the first genetically edited pig kidney transplant featuring 69 genomic edits. The commercial viability of these procedures is further supported by significant financial investment, exemplified by eGenesis securing $191 million in Series D financing in 2024 to advance their xenotransplantation pipeline toward clinical trials.

Market Challenge

The risk of zoonosis, specifically the potential transmission of infectious agents from animal donors to human recipients, presents a formidable barrier that directly impedes the growth of the Global Xenotransplantation Market. This safety issue compels regulatory bodies to enforce stringent precautionary measures, such as the requirement for biosecure breeding facilities and exhaustive screening for pathogens like porcine endogenous retroviruses. These rigorous demands significantly increase the complexity and cost of research and development, thereby extending the timeline for clinical trials and delaying the transition of xenotransplantation products from experimental stages to commercially viable therapies.

Furthermore, the inability to rapidly validate safety standards prevents the industry from scaling operations to meet the massive and immediate demand for organ replacement, leaving a large portion of the addressable market unserved. This bottleneck hinders the technology from bridging the gap between supply and demand; as noted by the United Network for Organ Sharing in 2024, more than 100,000 candidates remained on the U.S. waiting list while only 48,149 transplants were performed. This disparity underscores a substantial market opportunity that remains inaccessible largely due to unresolved challenges regarding zoonotic safety and the resulting regulatory hesitation.

Market Trends

A pivotal shift in the sector is the transition from preclinical studies and sporadic compassionate-use cases to structured, regulatory-approved First-in-Human Clinical Trials. This trend signifies the industry's progression toward gathering the standardized safety and efficacy data necessary for Biologics License Applications, creating a clear pathway for commercial approval and validating the manufacturing scalability of gene-edited organs. Illustrating this progress, United Therapeutics announced in February 2025 that it received FDA clearance for its Investigational New Drug Application to enroll an initial cohort of six patients in the UKidney Xenotransplantation Clinical Trial.

Concurrently, the commercial prioritization of xenogeneic kidney transplantation has emerged as a dominant strategic focus, with companies concentrating on renal indications because dialysis serves as a fallback therapy that mitigates the immediate lethal risks associated with graft failure compared to heart or liver procedures. Despite dialysis acting as a safety net, its limitations continue to drive the urgent pursuit of this application; eGenesis reported in September 2025, upon receiving IND clearance for EGEN-2784, that the five-year mortality rate for dialysis exceeds 50%. This statistic emphasizes the critical market necessity for viable xenogeneic alternatives to address the shortcomings of current renal replacement therapies.

Key Market Players

• United Therapeutics Corporation
• eGenesis, Inc.
• Novartis AG
• Astellas Pharma, Inc.
• F. Hoffmann-La Roche Ltd.
• Preservation Solutions, Inc.
• OrganOX Limited
• TransMedic, Pte. Ltd.
• Pfizer, Inc.
• Makana Therapeutics

Report Scope

In this report, the Global Xenotransplantation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Xenotransplantation Market, By Animal Type

• Pig
• Rabbit
• Baboon
• Others

Xenotransplantation Market, By Xeno Products

• Organs
• Tissues
• Cells

Xenotransplantation Market, By Organs

• Kidney
• Liver
• Heart
• Cornea
• Others

Xenotransplantation Market, By End Users

• Transplants Center
• Hospitals
• Others

Xenotransplantation Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Xenotransplantation Market.

Available Customizations:

Global Xenotransplantation Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Xenotransplantation Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Animal Type (Pig, Rabbit, Baboon, Others)
  • 5.2.2. By Xeno Products (Organs, Tissues, Cells)
  • 5.2.3. By Organs (Kidney, Liver, Heart, Cornea, Others)
  • 5.2.4. By End Users (Transplants Center, Hospitals, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Xenotransplantation Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Animal Type
  • 6.2.2. By Xeno Products
  • 6.2.3. By Organs
  • 6.2.4. By End Users
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Xenotransplantation Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Animal Type
      • 6.3.1.2.2. By Xeno Products
      • 6.3.1.2.3. By Organs
      • 6.3.1.2.4. By End Users
  • 6.3.2. Canada Xenotransplantation Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Animal Type
      • 6.3.2.2.2. By Xeno Products
      • 6.3.2.2.3. By Organs
      • 6.3.2.2.4. By End Users
  • 6.3.3. Mexico Xenotransplantation Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Animal Type
      • 6.3.3.2.2. By Xeno Products
      • 6.3.3.2.3. By Organs
      • 6.3.3.2.4. By End Users

7. Europe Xenotransplantation Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Animal Type
  • 7.2.2. By Xeno Products
  • 7.2.3. By Organs
  • 7.2.4. By End Users
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Xenotransplantation Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Animal Type
      • 7.3.1.2.2. By Xeno Products
      • 7.3.1.2.3. By Organs
      • 7.3.1.2.4. By End Users
  • 7.3.2. France Xenotransplantation Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Animal Type
      • 7.3.2.2.2. By Xeno Products
      • 7.3.2.2.3. By Organs
      • 7.3.2.2.4. By End Users
  • 7.3.3. United Kingdom Xenotransplantation Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Animal Type
      • 7.3.3.2.2. By Xeno Products
      • 7.3.3.2.3. By Organs
      • 7.3.3.2.4. By End Users
  • 7.3.4. Italy Xenotransplantation Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Animal Type
      • 7.3.4.2.2. By Xeno Products
      • 7.3.4.2.3. By Organs
      • 7.3.4.2.4. By End Users
  • 7.3.5. Spain Xenotransplantation Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Animal Type
      • 7.3.5.2.2. By Xeno Products
      • 7.3.5.2.3. By Organs
      • 7.3.5.2.4. By End Users

8. Asia Pacific Xenotransplantation Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Animal Type
  • 8.2.2. By Xeno Products
  • 8.2.3. By Organs
  • 8.2.4. By End Users
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Xenotransplantation Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Animal Type
      • 8.3.1.2.2. By Xeno Products
      • 8.3.1.2.3. By Organs
      • 8.3.1.2.4. By End Users
  • 8.3.2. India Xenotransplantation Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Animal Type
      • 8.3.2.2.2. By Xeno Products
      • 8.3.2.2.3. By Organs
      • 8.3.2.2.4. By End Users
  • 8.3.3. Japan Xenotransplantation Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Animal Type
      • 8.3.3.2.2. By Xeno Products
      • 8.3.3.2.3. By Organs
      • 8.3.3.2.4. By End Users
  • 8.3.4. South Korea Xenotransplantation Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Animal Type
      • 8.3.4.2.2. By Xeno Products
      • 8.3.4.2.3. By Organs
      • 8.3.4.2.4. By End Users
  • 8.3.5. Australia Xenotransplantation Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Animal Type
      • 8.3.5.2.2. By Xeno Products
      • 8.3.5.2.3. By Organs
      • 8.3.5.2.4. By End Users

9. Middle East & Africa Xenotransplantation Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Animal Type
  • 9.2.2. By Xeno Products
  • 9.2.3. By Organs
  • 9.2.4. By End Users
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Xenotransplantation Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Animal Type
      • 9.3.1.2.2. By Xeno Products
      • 9.3.1.2.3. By Organs
      • 9.3.1.2.4. By End Users
  • 9.3.2. UAE Xenotransplantation Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Animal Type
      • 9.3.2.2.2. By Xeno Products
      • 9.3.2.2.3. By Organs
      • 9.3.2.2.4. By End Users
  • 9.3.3. South Africa Xenotransplantation Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Animal Type
      • 9.3.3.2.2. By Xeno Products
      • 9.3.3.2.3. By Organs
      • 9.3.3.2.4. By End Users

10. South America Xenotransplantation Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Animal Type
  • 10.2.2. By Xeno Products
  • 10.2.3. By Organs
  • 10.2.4. By End Users
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Xenotransplantation Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Animal Type
      • 10.3.1.2.2. By Xeno Products
      • 10.3.1.2.3. By Organs
      • 10.3.1.2.4. By End Users
  • 10.3.2. Colombia Xenotransplantation Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Animal Type
      • 10.3.2.2.2. By Xeno Products
      • 10.3.2.2.3. By Organs
      • 10.3.2.2.4. By End Users
  • 10.3.3. Argentina Xenotransplantation Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Animal Type
      • 10.3.3.2.2. By Xeno Products
      • 10.3.3.2.3. By Organs
      • 10.3.3.2.4. By End Users

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Xenotransplantation Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. United Therapeutics Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. eGenesis, Inc.
• 15.3. Novartis AG
• 15.4. Astellas Pharma, Inc.
• 15.5. F. Hoffmann-La Roche Ltd.
• 15.6. Preservation Solutions, Inc.
• 15.7. OrganOX Limited
• 15.8. TransMedic, Pte. Ltd.
• 15.9. Pfizer, Inc.
• 15.10. Makana Therapeutics

16. Strategic Recommendations

17. About Us & Disclaimer